The Babich Family Foundation/RUNX1 Research Program is partnering with The Leukemia and Lymphoma Society (LLS) to launch a competitive grant to advance the understanding and treatment therapies of familial RUNX1 mutations leading to AML. The total grant monies is up to $1.8 million, encompassing 3 grants of $600,000 each.
Approximately 50% of patients with familial RUNX1 mutations will go on to develop AML upon a second mutation; additionally, RUNX1 mutations are found in 11-31% of patients with de novo and secondary AML, respectively. As it is poorly understood how RUNX1 mediates platelet defects and leads to AML, this grant program aims to fund cutting-edge, translational research to better the understanding of RUNX1 in leukemogenesis and to transform therapeutic options for pre- and post-leukemic patients.
Research proposals should include, but are not limited to: translational research involving therapeutics that re-activate RUNX1 or downstream pathways, gene editing, gene therapy, prognostic assays, lab research to understand RUNX1's biology, and the development of experimental systems that mimic FPD.
LOI Application deadline is January 13, 2017. Competition winners will be announced June 30, 2017 and grants activate October 1, 2017.
For more detail, instructions, and to apply see: https://lls.fluxx.io or email: [email protected].